Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers

European Journal of Clinical Pharmacology

Volumn 68, Issue 9, 2012, Pages 1275-1280

  Hegazy, Sahar K ^a   Mabrouk, Mokhtar M ^a   Elsisi, Alaa E ^a   Mansour, Noha O ^b  

^a TANTA UNIVERSITY   (Egypt)

^b Tanta University   (Egypt)

Author keywords

CYP2C9; CYP3A4; Montelukast; OATP; Pharmacokinetic interactions

Indexed keywords

CLARITHROMYCIN; FLUCONAZOLE; MONTELUKAST;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETATES; ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLARITHROMYCIN; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EGYPT; ENZYME INHIBITORS; FLUCONAZOLE; HALF-LIFE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; QUINOLINES;

EID: 84866620289     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1239-0     Document Type: Article

References (27)

1. Harmanci K, Bakirtas A, Turktas I, Degim T (2006) Oral montelukast treatment of preschool-aged children with acute asthma. Ann Allergy Asthma Immunol 96(5):731-735
2. Mougey EB, Feng H, Castro MG, Irvin GC, Lima JJ (2009) Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 19(2):129-138
3. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, Somers G (1996) Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK- 0476) in healthy males and females. Pharm Res 13:445-448
4. Merck. Singulair prescribing information. Available from: www. singulair.com/montelukast-sodium/singulair/consumer/adult/ asthma/product- information/pi/index.jsp . Accessed 12 Feb 2010
5. Chiba M, Xu X, Nishime JA, Balani SK, Lin JH (1997) Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist in humans. Drug Metab Dispos 25(11):1282-1287
6. Filppula AM, Laitila J, Neuvonen PJ, Backman JT (2011) Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos 39(5):904-911
7. Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT (2010) Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 88:223-230
8. Karonen T, Neuvonen PJ, Backman JT (2012) CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol 73:257-267
9. Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD (2010) Physiologically-based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 38:241-248
10. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, Dörje F, Mürdter TE, Ackermann A, Dormann H, Gassmann KG, Hahn EG, Zierhut S, Brune K, Fromm MF (2007) Role of pglycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 46(12):1039-1049
11. Alsarra IA (2004) Development of a stability-indicating HPLC method for the Determination of montelukast in tablets and human plasma, and its applications to pharmacokinetic and stability studies. Saudi Med J 12(4):136-143
12. Lee AJ, Maddix DS (2001) Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 35(1):26-31
13. Brophy DF, Israel DS, Pastor A, Gillotin C, Chittick GE, Symonds WT, Lou Y, Sadler BM, Polk RE (2000) Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob Agents Ch 44(4):978-984
14. Hedaya MA, El-Afify DR, El-Maghraby GM (2006) The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharm Drug Dispos 27(2):103-110
15. Zhou S, Chan E, Li X, Huang M (2005) Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 1(1):3-13
16. Seithel A, Eberl S, Singer K, Auge D, Heinkele G,Wolf NB, Dörje F, Fromm MF, König J (2007) The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 35(5):779-86
17. Lan T, Rao A, Haywood J, Davis CB, Han C, Garver E, Dawson PA (2009) Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Drug Metab Dispos 37(12):2375-82
18. Niwa T, Shiraga T, Takagi A, Zasshi Y (2005) Drug-drug interaction of antifungal drugs. Clin Pharmacol Ther 125(10):795-805
19. Kaukonen KM, Olkkola KT, Neuvonen PJ (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 53:445-449
20. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivist KT (2001) Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 69(4):194-200
21. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL (2004) Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 12(1):85-96
22. Huang L, Berry L, Ganga S, Janosky B, Chen A, Roberts J, Colletti AE, Lin MH (2010) Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab Dispos 38(2):223-231
23. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, Wang J, Sylvester J, Holbrook J, Wise R, Weiss ST, Barnes K (2006) Influence of leukotriene pathway polymorphisms on response to montelukastin asthma. Am J Respir Crit Care Med 173 (4):379-385
24. Zaghloul IY, Asiri AY, Alnaim LS, Al-Hadiya BM (2009) Coadministration of fluoxetine alters the steady state pharmacokinetics of fluconazole after multiple oral administration in dogs. Scholarly Research Exchange 834879. doi:10.3814/2009/834879
25. Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141-1160
26. Brüggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM (2009) Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48(10):1441-58
27. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW (2002) Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 46:160-165